F Moltzahn1, J Karnes2, P Gontero3, B Kneitz4, B Tombal5, P Bader6, A Briganti7, F Montorsi7, H Van Poppel8, S Joniau8, M Spahn1. 1. Department of Urology, University Hospital Bern, Bern, Switzerland. 2. Department of Urology, Mayo Clinic Rochester, Rochester, MN, USA. 3. Department of Urology, University of Turin, Turin, Italy. 4. Department of Urology and Pediatric Urology, University Hospital Wurzburg, Wurzburg, Germany. 5. Department of Urology, Université Catholique De Louvain, Brussels, Belgium. 6. Department of Urology, Community Hospital Karlsruhe, Karlsruhe, Germany. 7. Department of Urology, Hospital San Rafael, Milan, Italy. 8. Department of Urology, University Hospitals Leuven, Leuven, Belgium.
Abstract
BACKGROUND: The value of radical prostatectomy (RP) as an approach for very high-risk prostate cancer (PCa) patients is controversial. To examine the risk of 10-year cancer-specific mortality (CSM) and other-cause mortality (OCM) according to clinical and pathological characteristics of very high-risk cT3b/4 PCa patients treated with RP as the primary treatment option. METHODS: In a multi-institutional cohort, 266 patients with very high-risk cT3b/4 PCa treated with RP were identified. All patients underwent RP and pelvic lymph-node dissection. Competing-risk analyses assessed 10-year CSM and OCM before and after stratification for age and Charlson comorbidity index (CCI). RESULTS: Overall, 34 (13%) patients died from PCa and 73 (28%) from OCM. Ten-year CSM and OCM rates ranged from 5.6% to 12.9% and from 10% to 38%, respectively. OCM was the leading cause of death in all subgroups. Age and comorbidities were the main determinants of OCM. In healthy men, CSM rate did not differ among age groups (10-year CSM rate for ⩽64, 65-69 and ⩾70 years: 16.2%, 11.5% and 17.1%, respectively). Men with a CCI ⩾1 showed a very low risk of CSM irrespective of age (10-year CSM: 5.6-6.1%), whereas the 10-year OCM rates increased with age up to 38% in men ⩾70 years. CONCLUSION: Very high-risk cT3b/4 PCa represents a heterogeneous group. We revealed overall low CSM rates despite the highly unfavorable clinical disease. For healthy men, CSM was independent of age, supporting RP even for older men. Conversely, less healthy patients had the highest risk of dying from OCM while sharing very low risk of CSM, indicating that this group might not benefit from an aggressive surgical treatment. Outcome after RP as the primary treatment option in cT3b/4 PCa patients is related to age and comorbidity status.
BACKGROUND: The value of radical prostatectomy (RP) as an approach for very high-risk prostate cancer (PCa) patients is controversial. To examine the risk of 10-year cancer-specific mortality (CSM) and other-cause mortality (OCM) according to clinical and pathological characteristics of very high-risk cT3b/4 PCa patients treated with RP as the primary treatment option. METHODS: In a multi-institutional cohort, 266 patients with very high-risk cT3b/4 PCa treated with RP were identified. All patients underwent RP and pelvic lymph-node dissection. Competing-risk analyses assessed 10-year CSM and OCM before and after stratification for age and Charlson comorbidity index (CCI). RESULTS: Overall, 34 (13%) patients died from PCa and 73 (28%) from OCM. Ten-year CSM and OCM rates ranged from 5.6% to 12.9% and from 10% to 38%, respectively. OCM was the leading cause of death in all subgroups. Age and comorbidities were the main determinants of OCM. In healthy men, CSM rate did not differ among age groups (10-year CSM rate for ⩽64, 65-69 and ⩾70 years: 16.2%, 11.5% and 17.1%, respectively). Men with a CCI ⩾1 showed a very low risk of CSM irrespective of age (10-year CSM: 5.6-6.1%), whereas the 10-year OCM rates increased with age up to 38% in men ⩾70 years. CONCLUSION: Very high-risk cT3b/4 PCa represents a heterogeneous group. We revealed overall low CSM rates despite the highly unfavorable clinical disease. For healthy men, CSM was independent of age, supporting RP even for older men. Conversely, less healthy patients had the highest risk of dying from OCM while sharing very low risk of CSM, indicating that this group might not benefit from an aggressive surgical treatment. Outcome after RP as the primary treatment option in cT3b/4 PCa patients is related to age and comorbidity status.
Authors: Urs E Studer; Peter Whelan; Walter Albrecht; Jacques Casselman; Theo de Reijke; Dieter Hauri; Wolfgang Loidl; Santiago Isorna; Subramanian K Sundaram; Muriel Debois; Laurence Collette Journal: J Clin Oncol Date: 2006-04-20 Impact factor: 44.544
Authors: Axel Heidenreich; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Malcolm Mason; Vsevolod Matveev; Nicolas Mottet; Hans-Peter Schmid; Theo van der Kwast; Thomas Wiegel; Filliberto Zattoni Journal: Eur Urol Date: 2010-10-28 Impact factor: 20.096
Authors: Yu-Hsuan Shao; Kitaw Demissie; Weichung Shih; Amit R Mehta; Mark N Stein; Calpurnyia B Roberts; Robert S Dipaola; Grace L Lu-Yao Journal: J Natl Cancer Inst Date: 2009-08-27 Impact factor: 13.506
Authors: Timothy J Daskivich; Kang-Hsien Fan; Tatsuki Koyama; Peter C Albertsen; Michael Goodman; Ann S Hamilton; Richard M Hoffman; Janet L Stanford; Antoinette M Stroup; Mark S Litwin; David F Penson Journal: Ann Intern Med Date: 2013-05-21 Impact factor: 25.391
Authors: Urs E Studer; Peter Whelan; Florian Wimpissinger; Jacques Casselman; Theo M de Reijke; Hartmut Knönagel; Wolfgang Loidl; Santiago Isorna; Subramanian K Sundaram; Laurence Collette Journal: Eur Urol Date: 2013-07-24 Impact factor: 20.096
Authors: Joo Yong Lee; Ho Won Kang; Koon Ho Rha; Nam Hoon Cho; Young Deuk Choi; Sung Joon Hong; Kang Su Cho Journal: J Cancer Res Clin Oncol Date: 2015-12-12 Impact factor: 4.553
Authors: L Tosco; A Laenen; A Briganti; P Gontero; R J Karnes; M Albersen; P J Bastian; P Chlosta; F Claessens; F K Chun; W Everaerts; C Gratzke; M Graefen; B Kneitz; G Marchioro; R S Salas; B Tombal; T Van den Broeck; L Moris; A Battaglia; H van der Poel; J Walz; A Bossi; G De Meerleer; K Haustermans; H Van Poppel; M Spahn; S Joniau Journal: Prostate Cancer Prostatic Dis Date: 2017-05-09 Impact factor: 5.554
Authors: Thomas L Jang; Neal Patel; Izak Faiena; Kushan D Radadia; Dirk F Moore; Sammy E Elsamra; Eric A Singer; Mark N Stein; James A Eastham; Peter T Scardino; Yong Lin; Isaac Y Kim; Grace L Lu-Yao Journal: Cancer Date: 2018-09-25 Impact factor: 6.860